Palvella Therapeutics ((PVLA) announced that the FDA has granted Fast Track Designation to QTORIN rapamycin for the treatment of angiokeratomas. The company noted that, if relevant criteria are met, programs with Fast Track designation can become eligible for accelerated approval and priority review.
In September 2025, Palvella announced the expansion of QTORIN rapamycin development program into clinically significant angiokeratomas. The company plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 study of approximately 1020 patients, with study initiation expected in the second half of 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.